Aberrant activation of KMT2A‐target genes, part of a conserved stem‐cell program, is driven by KMT2A‐fusion oncogenes or activated by wild‐type KMT2A complexes as demonstrated specifically in NPM1mut leukemias.8, 46, 47, 48, 49, 50. Here, KMT2A is linked to leukemia.